Skip to content

MDMA for anxiety

Studies whose primary subject is both MDMA and Anxiety, with an evidence synthesis read across the most-cited and most recent of them.

State of the evidence

Synthesized

Synthesized from 24 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for MDMA, ecstasy, molly, methylenedioxymethamphetamine, Anxiety, generalized anxiety disorder, then ranked by relevance.

The research on MDMA for anxiety is mixed and depends heavily on context. In clinical trials where MDMA is given with psychotherapy, small pilot studies in autistic adults and people with life-threatening illness report large reductions in anxiety (one trial significant, one just short of significance), and an open-label trial in social anxiety disorder found a large benefit versus waitlist. However, observational studies of recreational ecstasy users consistently link use to more anxiety and mood problems, and a large longitudinal cohort found higher odds of anxiety disorders in later adulthood. The main caveats are very small samples, unblinding concerns, and the fact that most positive evidence comes from preliminary trials.

Evidence by study

Direction is which way each study's own result points, not our rating of the study.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.
Study Design Sample size Direction Finding
Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. 2018 RCT 12 Supports MDMA-assisted psychotherapy produced significantly greater and durable improvement in social anxiety symptoms than placebo, with very large effect sizes at one month and six months.
MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study 2020 RCT 18 Supports MDMA-assisted psychotherapy led to a greater reduction in anxiety scores than placebo, but the group difference did not reach statistical significance (p = .056).
MDMA-Assisted Therapy for Social Anxiety Disorder: A Randomized, Open-label, Wait-list Controlled Trial 2026 RCT 20 Supports MDMA-assisted therapy led to a significantly greater reduction in social anxiety symptoms than a waitlist condition, with a mean difference of -43.3 on the Liebowitz Social Anxiety Scale.
Therapeutic Alliance and Perceived Closeness in MDMA-Assisted Therapy for Social Anxiety Disorder 2026 secondary analysis of open-label pilot trial 20 Supports Greater perceived closeness to the therapist during MDMA sessions predicted lower post-treatment social anxiety, and therapeutic alliance increased significantly after the first MDMA session.
The relationship between 3,4-methylenedioxymethamphetamine (MDMA) use in young adulthood and anxiety or depressive disorders in the mid-30s: Findings from the Victorian Adolescent Health Cohort Study. 2025 longitudinal cohort 1943 Opposes MDMA use in early adulthood was associated with higher adjusted odds of anxiety disorders by the mid-30s, with little evidence linking it to depressive disorders.
Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users 2002 cross-sectional survey 282 Opposes The incidence of psychobiological problems attributed to ecstasy use, including anxiety, was directly related to the number of occasions it had been used.
Long-Term Neuropsychiatric Consequences of "Ecstasy" (MDMA): A Review 2002 review Opposes Repeated ecstasy use was associated with persistent sleep, mood, and anxiety disturbances that may persist for up to two years after cessation.
Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms 2001 observational cohort 29 Opposes Former chronic ecstasy users reported significantly higher levels of depression than matched non-drug-using controls.
No Difference in Brain Activation During Cognitive Performance Between Ecstasy (3,4-Methylenedioxymethamphetamine) Users and Control Subjects: A [H215O]-Positron Emission Tomography Study 2001 observational cohort Opposes Polytoxic ecstasy users had significantly higher levels of depressiveness than controls, though no differences in regional cerebral blood flow or cognitive task performance were observed.
Mood state and brain electric activity in Ecstasy users 2000 observational cohort 29 Mixed Ecstasy users had higher state depressiveness and emotional excitability and a trend-level increase in state anxiety, alongside global EEG power increases.
Gender differences in the subjective effects of MDMA 2001 pooled analysis of three double-blind placebo-controlled studies 74 Mixed Women experienced more intense psychoactive effects and more adverse effects from MDMA than men, including higher scores for fear of loss of body control, while men had greater blood pressure increases.
A review of the acute subjective effects of MDMA/ecstasy 2006 systematic review Mixed Anxiety was among the most frequently reported acute subjective effects of MDMA/ecstasy, alongside other emotional and somatic effects.
How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale 2009 theoretical paper Supports Argues that MDMA-augmented psychotherapy may treat treatment-resistant anxiety disorders through increased oxytocin, altered prefrontal and amygdala activity, and elevated norepinephrine and cortisol.
MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults. 2016 review 1133 Supports Argues that MDMA has been safely administered to over 1133 individuals in research and that its infrequent dosing may offer a favorable risk/benefit ratio for treating social anxiety in autistic adults.
MDMA in Psychiatry: From PTSD to emerging indications, safety, and future directions 2025 review Mixed Notes that early randomized placebo-controlled studies suggest benefits for anxiety related to life-threatening illness, while regulatory approval has been delayed over concerns about functional unblinding and protocol rigor.
A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses 2020 review Supports Reports that accumulated research suggests psychedelics including MDMA may emerge as breakthrough therapies for psychiatric conditions refractory to conventional treatments, including end-of-life anxiety.
Clinical applications of hallucinogens: A review. 2016 review Supports Argues that a growing body of evidence indicates hallucinogens including entactogens may have therapeutic applications beyond their potential for abuse.
Ecstasy (MDMA) for social anxiety in autism: a specialized application of empathogen therapy 2026 narrative review / commentary Supports States that MDMA-assisted psychotherapy significantly reduces social fear and anxiety in autistic adults in a pilot trial, but notes that further large-scale safety trials are needed.
3,4-Methylenedioxymethamphetamine facilitates fear extinction learning 2015 preclinical experimental study Supports MDMA persistently enhanced long-term fear extinction learning through a BDNF-dependent mechanism in the amygdala.
MDMA and psilocybin regulate oligodendrocyte-lineage cell numbers and anxiety-like behaviors in a rat model of fear. 2026 experimental study in an animal model 210 Supports Psilocybin and MDMA reduced anxiety-like behaviors in a rat model of contextual fear conditioning, and myelin disruption abolished these anxiolytic effects.
A repeated low-dose regimen of MDMA has transient next-day effects on locomotor activity, anxiety-like behavior, and brain serotonin levels, with no effect on anhedonia-like behavior, in both female and male rats 2026 experimental study Mixed Repeated low-dose MDMA produced transient mild anxiety-like behavior and reduced nucleus accumbens serotonin one day after exposure, with no lasting effects at 15 days.
Questions and Concerns About MDMA-Assisted Therapy (MDMA-AT) in Veterans with PTSD Symptoms 2025 qualitative study 30 Mixed At least one third of veterans mentioned hope and curiosity about MDMA-assisted therapy for PTSD alongside concerns about side effects, subjective effects, and addictive potential.
Investigating the Role of Self-Compassion in MDMA-Assisted Therapy for Social Anxiety Disorder 2026 study protocol Unclear Describes a preregistered protocol to test whether self-compassion is a mechanism of therapeutic change in MDMA-assisted therapy for social anxiety disorder.
Partydrogen im Überblick 2026 review Unclear Describes party drugs including MDMA as having diverse pharmacological mechanisms and both acute and long-term risks that vary by substance, use patterns, and context.

Points of agreement

  • Small placebo-controlled and open-label trials of MDMA-assisted psychotherapy in autistic adults, people with life-threatening illness, and social anxiety disorder consistently report reductions in anxiety symptoms.
  • Observational studies of recreational ecstasy users consistently associate use with higher anxiety, depression, and mood disturbance.
  • Animal studies suggest MDMA can enhance fear extinction and reduce anxiety-like behavior through neuroplasticity-related mechanisms.
  • Reviews note that positive clinical findings are preliminary and that unblinding and protocol rigor are unresolved concerns.

Conflicts

  • Clinical trials report anxiety reductions from MDMA-assisted psychotherapy, while observational studies of recreational users report increased anxiety and mood problems.
  • One randomized trial in life-threatening illness found a large but non-significant anxiety reduction, while another in social anxiety disorder found a significant and very large reduction.
  • Animal studies show both anxiolytic effects and transient anxiety-like behavior depending on dose and timing.

Gaps

  • Most positive clinical trials have very small samples (12-20 participants).
  • Blinding integrity is questionable in MDMA trials due to the drug's subjective effects.
  • Long-term durability of anxiety reductions beyond six to twelve months is largely unstudied.
  • Optimal dosing, number of sessions, and psychotherapy protocols are not standardized.
  • Populations studied are narrow (autistic adults, life-threatening illness, social anxiety disorder); other anxiety disorders are understudied.
  • Mechanisms of therapeutic change, including self-compassion and therapeutic alliance, remain under investigation.
Browse these studies in the library

Common questions

What does the research agree on about MDMA for anxiety?
  • Small placebo-controlled and open-label trials of MDMA-assisted psychotherapy in autistic adults, people with life-threatening illness, and social anxiety disorder consistently report reductions in anxiety symptoms.
  • Observational studies of recreational ecstasy users consistently associate use with higher anxiety, depression, and mood disturbance.
  • Animal studies suggest MDMA can enhance fear extinction and reduce anxiety-like behavior through neuroplasticity-related mechanisms.
  • Reviews note that positive clinical findings are preliminary and that unblinding and protocol rigor are unresolved concerns.
Where do studies on MDMA for anxiety conflict?
  • Clinical trials report anxiety reductions from MDMA-assisted psychotherapy, while observational studies of recreational users report increased anxiety and mood problems.
  • One randomized trial in life-threatening illness found a large but non-significant anxiety reduction, while another in social anxiety disorder found a significant and very large reduction.
  • Animal studies show both anxiolytic effects and transient anxiety-like behavior depending on dose and timing.
What is still unknown about MDMA for anxiety?
  • Most positive clinical trials have very small samples (12-20 participants).
  • Blinding integrity is questionable in MDMA trials due to the drug's subjective effects.
  • Long-term durability of anxiety reductions beyond six to twelve months is largely unstudied.
  • Optimal dosing, number of sessions, and psychotherapy protocols are not standardized.
  • Populations studied are narrow (autistic adults, life-threatening illness, social anxiety disorder); other anxiety disorders are understudied.
  • Mechanisms of therapeutic change, including self-compassion and therapeutic alliance, remain under investigation.
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is MDMA for anxiety, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when MDMA for anxiety or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

The full method, including what a person does and does not review, is on the methods page.

Ask your own question in the Research Synthesis Tool

81 articles · 16 from the last two years · 7,612 participants across 36 studies reporting sample size

Common study designs

review 26 case study 3 systematic review 6 observational cohort 5 randomized controlled trial 9

Research volume by year

Compare topics →

75 studies whose primary subject is MDMA for anxiety since 2002

Studies about MDMA for anxiety per year, 2002 to 2026, peaking at 12 in 2023 Bar chart: one bar per year, taller where more studies were published that year. 0 10 20 2005 2010 2015 2020 2025
2026 is partial
Show the numbers
Studies about MDMA for anxiety per year, 2002 to 2026, peaking at 12 in 2023
Year Studies
2002 2
2003 0
2004 1
2005 0
2006 4
2007 1
2008 0
2009 1
2010 1
2011 0
2012 0
2013 1
2014 1
2015 2
2016 2
2017 3
2018 2
2019 2
2020 2
2021 8
2022 8
2023 12
2024 6
2025 9
2026 7

Research

Synthesize the evidence →

Therapeutic Alliance and Perceived Closeness in MDMA-Assisted Therapy for Social Anxiety Disorder

September 11, 2026 Joseph M. Diehl, Christina Chwyl, Liliana Kennedy et al. preprint

The therapeutic relationship is considered central to psychedelic-assisted therapy, yet little empirical research has examined how it changes during 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) or relates to acute MDMA experiences and clinical outcomes, particularly for social anxiety disorder (SAD). This preregistered secondary analysis examined therapeutic alliance and...

DOI: 10.31234/osf.io/tezgw_v1 (opens in new tab)

MDMA-Assisted Therapy for Social Anxiety Disorder: A Randomized, Open-label, Wait-list Controlled Trial

June 4, 2026 Jason B. Luoma, M. Kati Lear, Brian Pilecki et al. preprint

Background: ±3,4-methylenedioxymethamphetamine (MDMA) has positive effects on socio-emotional processing and MDMA-Assisted Therapy (MDMA-AT) showed promise for treating SAD in a previous placebo-controlled trial. Aims: Develop a preliminary estimate of clinical response and safety for MDMA-AT versus waitlist in adults with SAD. Secondary aims included refinement of a standardized psychotherapy...

DOI: 10.31234/osf.io/a9x6d_v1 (opens in new tab) Social anxiety Randomized controlled trial Adverse effect Clinical trial +3

Ecstasy (MDMA) for social anxiety in autism: a specialized application of empathogen therapy

Annals of Medicine and Surgery April 6, 2026 Mahnoor Sheikh, Zaibunnisa Bilal, Syeda Habiba Fatima et al.

To the Editor, Autism spectrum disorder (ASD) is a neurodevelopmental state in which there are early emerging problems in social communication along with fixed behavior patterns. Social difficulties in ASD are characterized by difficulty in interpretation of interpersonal signals such as facial expressions, tone of voice, and body language. Individuals with ASD often present with social...

DOI: 10.1097/ms9.0000000000004936 (opens in new tab) Ecstasy Social anxiety Social skills Social inhibition +14

A repeated low-dose regimen of MDMA has transient next-day effects on locomotor activity, anxiety-like behavior, and brain serotonin levels, with no effect on anhedonia-like behavior, in both female and male rats

Psychopharmacology March 4, 2026 Ava M. Mac, Srinivasu Kallakuri, Alixandria T. Mascarin et al.

MDMA (3–4 methylenedioxymethamphetamine) assisted psychotherapy has gained considerable attention as a potential adjuvant therapy for post-traumatic stress disorder (PTSD). Reports of the nonmedical use of MDMA suggest its adverse effects may include anxiety and anhedonia. However, the time course of these signs and symptoms and the potential alterations in neurotransmitter levels that may...

DOI: 10.1007/s00213-026-07010-1 (opens in new tab) Full text (opens in new tab) MDMA Serotonin Serotonergic Monoamine neurotransmitter +13

MDMA and psilocybin regulate oligodendrocyte-lineage cell numbers and anxiety-like behaviors in a rat model of fear.

Biological Psychiatry February 3, 2026 Mehmet Bostancıklıoğlu, Davut Sinan Kaplan, Ramazan Bal et al.

Psilocybin and 3,4-methylenedioxymethamphetamine (MDMA) produce rapid, enduring therapeutic effects in post-traumatic stress disorder (PTSD); however, the underlying cellular mechanisms remain incompletely understood. This study investigated whether adult myelin plasticity contributes to the therapeutic actions of psilocybin and MDMA in a rat model of contextual fear conditioning. Adult male...

DOI: 10.1016/j.biopsych.2026.01.016 (opens in new tab) Full text (opens in new tab) MDMA Psilocybin Fear-related behaviors Myelination +2

Partydrogen im Überblick

Psychopharmakotherapie 2026 Antonia Bendau, Felix Betzler, Twyla Michnevich et al. 1 citation

Party drugs encompass a broad spectrum of legal and illegal psychoactive substances used in party settings such as clubs, festivals, raves or private gatherings to modulate mood, perception, social interaction and bodily states. Most commonly, alcohol and cannabis are consumed, followed by amphetamine, MDMA (“ecstasy”), cocaine and ketamine. Synthetic cathinones, GHB/GBL (“liquid ecstasy”),...

DOI: 10.52778/ppt20260001 (opens in new tab) Serotonergic MDMA Addiction Cannabis +16

Investigating the Role of Self-Compassion in MDMA-Assisted Therapy for Social Anxiety Disorder

Open Science Framework 2026 Christina Chwyl, M. Kati Lear, Sunjeev K. Kamboj et al.

Self-compassion is theorized to play a central role in promoting mental health and wellbeing, including for individuals with social anxiety disorder (SAD). One proposed mechanism of MDMA-assisted therapy (MDMA-AT) for SAD is the cultivation of self-compassion. Across five aims, we will characterize self-compassion experiences during MDMA-AT and evaluate its role as a potential mechanism of...

DOI: 10.17605/osf.io/p8du5 (opens in new tab) Major depressive disorder Social anxiety Dosing Mechanism biology +5

The relationship between 3,4-methylenedioxymethamphetamine (MDMA) use in young adulthood and anxiety or depressive disorders in the mid-30s: Findings from the Victorian Adolescent Health Cohort Study.

Addiction (Abingdon, England) December 1, 2025 Zachary Bryant, Kirsten Morley, Jessica A Kerr et al.

MDMA (3,4-methylenedioxymethamphetamine or "Ecstasy") is the fourth-most used illicit substance globally. While previous research found links between MDMA use and mental health outcomes, the direction and nature of this relationship remain unclear. This study assessed whether MDMA use in early adulthood increases the risk of anxiety or depression in mid-30s. A longitudinal, population-based...

DOI: 10.1111/add.70173 (opens in new tab) Full text (opens in new tab) MDMA Anxiety Depression 3,4‐methylenedioxymethamphetamine +5

MDMA in Psychiatry: From PTSD to emerging indications, safety, and future directions

Psychedelics. October 14, 2025 Mingming Zhao, Jianjun Yang, Kenji Hashimoto

MDMA, 3,4-methylenedioxymethamphetamine (“ecstasy,” “molly”), is a distinctive entactogen that reverses the serotonin (5-HT) transporter to increase synaptic 5-HT, while also engaging catecholaminergic and oxytocinergic pathways. In clinical trials, MDMA-assisted psychotherapy has yielded substantial improvements in treatment-resistant posttraumatic stress disorder (PTSD), although regulatory...

DOI: 10.61373/pp025i.0035 (opens in new tab) MDMA Anxiety Neuroplasticity Cognition +5

Questions and Concerns About MDMA-Assisted Therapy (MDMA-AT) in Veterans with PTSD Symptoms

Journal of Psychoactive Drugs October 10, 2025 Mitch Earleywine, Caitlin Holley, Henry A MacConnel et al.

MDMA-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) shows promise, but attitudes and beliefs about this treatment, especially in symptomatic veterans, remain poorly understood. We sought to explore relevant attitudes in veterans receiving healthcare from Veterans Affairs as a step toward designing relevant surveys or psychoeducation materials for future work. We employed a...

DOI: 10.1080/02791072.2025.2570938 (opens in new tab) Anxiety Psychoeducation Curiosity Narrative +11

Clinical trials

All mdma for anxiety trials →